Home › Diffuse Large B-Cell Lymphoma › Montana › Billings
Diffuse Large B-Cell Lymphoma clinical trials in Billings, MT
3 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Billings (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RecruitingPhase 2
- Billings Clinic Cancer Center, Billings
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RecruitingPhase 2/3
- St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPhase 3
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178), Billings
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Milwaukee, WI16 studies
- Boston, MA16 studies
- Philadelphia, PA15 studies
- Portland, OR15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
Other studies in Billings
- Non-Small Cell Lung Cancer17 studies
- Prostate Cancer15 studies
- Lung Cancer13 studies
- Breast Cancer10 studies
- Ovarian Cancer8 studies
- Chronic Lymphocytic Leukemia7 studies
- Melanoma7 studies
- Bladder Cancer6 studies
- Colorectal Cancer6 studies
- Acute Myeloid Leukemia6 studies
- Colon Cancer6 studies
- Endometrial Cancer5 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.